Vacunas basadas en neoantígenos y control del cáncer: perspectivas

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75. https://doi.org/10.1016/S0140-6736(17)33326-3

Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the Evolution of Cancer Treatment Therapies. Cancers (Basel). 2011;3(3):3279-330. https://doi.org/10.3390/cancers3033279

Murillo R, Wiesner C, Acosta J, Piñeros M, Pérez JJ, Orozco M. Modelo para el cuidado del cáncer en Colombia. Bogotá: Serie Documentos Técnicos INC No. 5; 2015.

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57-70. https://doi.org/10.1016/S0092-8674(00)81683-9

Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018;9:1300. https://doi.org/10.3389/fphar.2018.01300

World Health Organization. Pricing of Cancer Medicines and its Impacts. Geneva: WHO; 2018.

Albrecht B, Menu P, Tsao J, Webster K. The Next Wave of Innovation in Oncology. McKinsey Cancer Center. McKinsey&Company; 2016.

Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value Health. 2017;20(3):487-95. https://doi.org/10.1016/j.jval.2016.10.011

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, et al. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018;6(1):69. https://doi.org/10.1186/s40425-018-0377-z

Hodi FS, O'Day, SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New Eng J Med. 2010;363(8):711-23. https://doi.org/10.1056/NEJMoa1003466

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35. https://doi.org/10.1056/NEJMoa1504627

Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12(1):93. https://doi.org/10.1186/s13045-019-0787-5

Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128. https://doi.org/10.1186/s12943-019-1055-6

Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168-82. https://doi.org/10.1038/nri.2017.131

Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, et al. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. J Immunol Res. 2018;2018:4325874. https://doi.org/10.1155/2018/4325874

Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013

Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol. 2014;10(1):41-62. https://doi.org/10.1586/1744666X.2014.865519

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459): eaat7807. https://doi.org/10.1126/scitranslmed.aat7807

Schumacher TN, Scheper W, Kvistborg P. Cancer Neoantigens. Annu Rev Immunol. 2019;37:173-200. https://doi.org/10.1146/annurev-immunol-042617-053402

Chu Y, Liu Q, Wei J, Liu B. Personalized cancer neoantigen vaccines come of age. Theranostics. 2018;8(15):4238-46. https://doi.org/10.7150/thno.24387

Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. https://doi.org/10.1038/s41541-019-0103-y

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA Mutanome Vaccines Mobilize Poly-Specific Therapeutic Immunity Against Cancer. Nature. 2017;547(7662):222-6. https://doi.org/10.1038/nature23003

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-21. https://doi.org/10.1038/nature22991

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234-9. https://doi.org/10.1038/s41586-018-0792-9

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74. https://doi.org/10.1126/science.aaa4971

Castle JC, Uduman M, Pabla S, Stein RB, Buell JS. Mutation-Derived Neoantigens for Cancer Immunotherapy. Front Immunol. 2019;10:1856. https://doi.org/10.3389/fimmu.2019.01856

Aurisicchio L, Pallocca M, Ciliberto G, Palombo F. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res. 2018;37(1):86. https://doi.org/10.1186/s13046-018-0751-1

Koşaloğlu-Yalçın Z, Lanka M, Frentzen A, Logandha Ramamoorthy Premlal A, Sidney J, Vaughan K, et al. Predicting T cell recognition of MHC class I restricted neoepitopes. Oncoimmunology. 2018;7(11):e1492508. https://doi.org/10.1080/2162402X.2018.1492508

Aldous AR, Dong JZ. Personalized neoantigen vaccines: a new approach to cancer immunotherapy. Bioorg Med Chem. 2018;26(10):2842-9. https://doi.org/10.1016/j.bmc.2017.10.021

Murillo R, Robles C. Research Needs for Implementing Cancer Prevention and Early Detection in Developing Countries: From Scientists' to Implementers' Perspectives. Biomed Res Int. 2019;2019:9607803. https://doi.org/10.1155/2019/9607803

World Health Organization. Global Report on Cancer. Geneva: WHO; 2020; in press.

Nature Editorial. A call for pragmatism in cancer research. Nat Rev Clin Oncol. 2018;15(4):193. https://doi.org/10.1038/nrclinonc.2018.41

Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019;19(6):349-58. https://doi.org/10.1038/s41568-019-0142-8

Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics. 2017;7(14):3585-94. https://doi.org/10.7150/thno.21471

International Agency for Research on Cancer/World Health Organization. Global Cancer Observatory [Internet]. Lyon: IARC; 2018. [Consultado el 15 de enero de 2020]. Disponible en: http://gco.iarc.fr

Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016;6(12):1382-99. https://doi.org/10.1158/2159-8290.CD-16-0577

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clin Cancer Res. 2019;25(19):5743-51. https://doi.org/10.1158/1078-0432.CCR-18-2641

Moscow JA, Fojo T, Schilsky RL. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018;15(3):183-92. https://doi.org/10.1038/nrclinonc.2017.186